WUXI XDC(02268.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
WUXI XDC
02268.HK
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.
818.89 B
02268.HKMarket value -Rank by Market Cap -/-

Financial Score

17/01/2026 Update
B
Life Sciences Tools and ServicesIndustry
Industry Ranking3/14
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE19.76%A
    • Profit Margin26.08%A
    • Gross Margin36.11%C
  • Growth ScoreA
    • Revenue YoY82.28%A
    • Net Profit YoY123.55%A
    • Total Assets YoY48.84%A
    • Net Assets YoY26.54%A
  • Cash ScoreB
    • Cash Flow Margin383.39%C
    • OCF YoY82.28%A
  • Operating ScoreB
    • Turnover0.57B
  • Debt ScoreB
    • Gearing Ratio29.94%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CICC Sticks to Its Buy Rating for WuXi XDC Cayman, Inc. (2268)

    In a report released yesterday, from CICC maintained a Buy rating on WuXi XDC Cayman, Inc., with a price target of HK$88.00.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Currently, the analyst consensus on WuXi XDC Cayman, Inc. is a Strong Buy with an average price target of HK$83.59.

    Tip Ranks·
    HK
    02268
    -2.81%
    Tip Ranks·
    HK
    02268
    -2.81%

    HSBC Research lists the best stocks in global emerging markets for this year (Table)

    HSBC Global Research released the list of the best stocks in global emerging markets for 2026, including 26 stocks. The stocks listed in Hong Kong are Tencent, HORIZONROBOT-W, and WUXI XDC. The target prices are: Tencent HKD 770, HORIZONROBOT-W HKD 11, WUXI XDC HKD 90.5. Stocks from other regions include Samsung Electronics, Trip.com, MercadoLibre, and others

    AASTOCKS·
    US
    TCEHY
    -1.97%
    US
    TCTZF
    -4.53%
    HK
    00700
    -0.72%
    AASTOCKS·
    US
    TCEHY
    -1.97%
    US
    TCTZF
    -4.53%
    HK
    00700
    -0.72%

    Daiwa: WUXI XDC proposes to fully acquire Dongyao Pharmaceutical and gives WuXi Biologics a "Buy" rating

    Daiwa released a research report stating that WuXi Biologics and WUXI XDC plan to acquire at least 60% of Dongyao Pharmaceutical for approximately 2.8 billion yuan, and it is expected that Dongyao Pharmaceutical will continue to be listed after the acquisition. This move will help WUXI XDC expand its business, enhance its production capacity in China, and consolidate its market position in the ADC contract research and manufacturing sector. Daiwa has given WuXi Biologics an investment rating of "Buy."

    AASTOCKS·
    HK
    02268
    -2.81%
    HK
    01875
    +1.67%
    US
    WXXWY
    +1.60%
    AASTOCKS·
    HK
    02268
    -2.81%
    HK
    01875
    +1.67%
    US
    WXXWY
    +1.60%

    Brief News: WUXI XDC issues profit warning, expects last year's profit to increase by 38%

    WUXI XDC Biotechnology Co., Ltd. expects a 45% year-on-year increase in total revenue for the full year of 2025, with a net profit growth of 38%, mainly due to optimized product and service profit margins and effective cost control. The company also proposed to acquire Voyah at HKD 4 per share, totaling approximately HKD 2.79 billion, with the acquisition price being 60% higher than before the suspension of trading. WUXI XDC's stock price fell 2.3% to HKD 74, while Voyah's stock price surged 58.8% to HKD 3.97

    BambooWorks·
    HK
    02268
    -2.81%
    HK
    01875
    +1.67%
    BambooWorks·
    HK
    02268
    -2.81%
    HK
    01875
    +1.67%

    Voyah Pharmaceuticals surged 57% after receiving a 60% premium offer from WUXI XDC for acquisition

    Voyah received a 60% premium takeover offer from WUXI XDC. After resuming trading, the stock price peaked at HKD 3.97 and is currently reported at HKD 3.93, up 57.2%. WUXI XDC plans to acquire all shares of Voyah using internal resources at a cash price of HKD 4 per share. After the transaction, Voyah will become a subsidiary of WUXI XDC and WuXi Biologics, continuing to be listed on the Hong Kong Stock Exchange. This transaction will help WUXI XDC expand its manufacturing capacity in China and strengthen its market position

    AASTOCKS·
    HK
    01875
    +1.67%
    HK
    02268
    -2.81%
    AASTOCKS·
    HK
    01875
    +1.67%
    HK
    02268
    -2.81%
    © 2026 Longbridge｜Disclaimer